Skip to content

NMIN researchers discuss the current state of CRISPR/Cas9 editing

In a new review article in Human Gene Therapy, NMIN researcher Dr. Colin Ross and NMIN HQP Tiffany Carlaw and Lin-Hua Zhang provide an overview of the current state of CRISPR/Cas9 base and prime editing technologies.

“Therapeutic base editing is one form of genome engineering that has gained much interest because of its simplicity, specificity, and effectiveness,” observe the authors, all of whom are based at the Colin Ross Laboratory at the University of British Columbia (UBC).

“However, in the past year, research has identified new safety concerns of base editors and sparked new innovations to improve their safety.”

Their review provides an overview of the recent advances in the safety and effectiveness of therapeutic base editors and prime editing.

“We think this may be of interest to many members of NMIN and the broader scientific community, as it breaks down these cutting-edge technologies and points to potential future innovations and developments in this field,” comments lead author Tiffany Carlaw.

Read the article